AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent $9 billion ...
The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...
AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...
AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on schizophrenia asset emraclidine missed the primary endpoint. AbbVie ...
In the last three months, 11 analysts have published ratings on AbbVie ABBV, offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...
Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which reported positive Phase 3 data. Bristol's Cobenfy is now poised to dominate the ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham from Citi reiterated a Buy rating on the stock and has a $ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback